<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2962">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04334629</url>
  </required_header>
  <id_info>
    <org_study_id>282009</org_study_id>
    <nct_id>NCT04334629</nct_id>
  </id_info>
  <brief_title>LIBERATE Trial in COVID-19</brief_title>
  <acronym>LIBERATE</acronym>
  <official_title>Lipid Ibuprofen Versus Standard of Care for Acute Hypoxemic Respiratory Failure Due to COVID-19: a Multicentre, Randomised, Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>King's College London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Guy's &amp; St Thomas NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>King's College London</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims to evaluate the reduction in severity and progression of lung injury with
      three doses of lipid ibuprofen in patients with SARS-CoV-2 infections.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">May 26, 2020</start_date>
  <completion_date type="Anticipated">May 25, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 25, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease progression</measure>
    <time_frame>14 days</time_frame>
    <description>Worsening respiratory failure; defined using severity of hypoxaemia using [PaO2/FiO2 ratio OR SpO2/FiO2 ratio]</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to mechanical ventilation</measure>
    <time_frame>14 days</time_frame>
    <description>Time to mechanical ventilation (or need of)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in proportion of patients who require ventilation</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in length of Critical Care stay</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in length of Hospital stay</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modulation of serum pro- and anti-inflammatory cytokines</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in duration of ventilation</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Increase in ventilator-free days</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">230</enrollment>
  <condition>Coronavirus</condition>
  <condition>Respiratory Distress Syndrome</condition>
  <condition>SARS-CoV Infection</condition>
  <arm_group>
    <arm_group_label>Standard of care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of care plus lipid ibuprofen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibuprofen</intervention_name>
    <description>Lipid ibuprofen 200 mg</description>
    <arm_group_label>Standard of care plus lipid ibuprofen</arm_group_label>
    <other_name>Flarin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female patients aged 18 years and above;

          2. Hospitalised;

          3. Confirmed or suspected SARS-CoV-2 infection;

          4. National Early Warning Score (NEWS2) greater than or equal to 3 in a single parameter
             or NEWS2 &gt; 5 overall;

          5. Acute hypoxemic respiratory failure: PaO2/FiO2 ratio less than or equal to 300 OR
             SpO2/FiO2 ratio &lt; 315 (Kigali Modification)

          6. Provision of written informed consent by the patient OR by the patient's Legal
             Representative OR professional consultee.

        Exclusion Criteria:

          1. Any of the following contraindications to ibuprofen:

               -  A known hypersensitivity to ibuprofen or any other constituent of the medicinal
                  product;

               -  Patients who have previously shown hypersensitivity reactions (e.g. asthma,
                  rhinitis, angioedema or urticaria) in response to aspirin or other non-steroidal
                  anti-inflammatory drugs (NSAIDs);

               -  Patients with a history of, or existing gastrointestinal ulceration/perforation
                  or bleeding, including that associated with NSAIDs;

               -  Patients with severe hepatic failure;

               -  Patients with acute renal failure;

               -  Patients with severe heart failure.

          2. Participation in any other investigational drug products less than 30 days prior to
             study enrolment;

          3. Glasgow Coma Score &lt; 12;

          4. Patients who cannot swallow oral capsules;

          5. Pregnant or lactating women;

          6. Any medical history that might, in the opinion of the attending clinician, put the
             patient at significant risk if he/she were to participate in the trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Beale, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Guy's and St Thomas' NHS Foundation Trust</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ndaba Mazibuko, MD</last_name>
    <phone>02078485452</phone>
    <email>ndaba.mazibuko@nhs.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Chloe Farrell, PhD</last_name>
    <phone>02078485452</phone>
    <email>chloe.farrell@kcl.ac.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Guy's and St Thomas' NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chloe Farrell, PhD</last_name>
      <phone>02078485452</phone>
      <email>chloe.farrell@kcl.ac.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>April 2, 2020</study_first_submitted>
  <study_first_submitted_qc>April 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 6, 2020</study_first_posted>
  <last_update_submitted>May 26, 2020</last_update_submitted>
  <last_update_submitted_qc>May 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ibuprofen</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

